受体介导的反义治疗研究

张春

受体介导的反义治疗研究

张春

文章导航 > 国际放射医学核医学杂志 > 2000, 24 > 3: (104-106)

引用本文:

Citation:

受体介导的反义治疗研究

张春

610041 成都, 华西医科大学附一院核医学科

作者简介: 张春(1973-),女,山西长治人,华西医科大学附属第一医院核医学科住院医师,博士研究生,主要从事反义治疗研究。;

基金项目:
国家自然科学基金(39870200)
中图分类号: R817. 5

Receptor-mediated antisense therapy studies

Zhang Chun

Department of Nuclear Medicine the Affilated Hospital the West China University of Medical Sciences Sichuan Chengdu 610041, China
CLC number: R817. 5

摘要: 受体介导的反义治疗是利用受体与配体高特异性、高亲和力结合的特点,通过受体介导的内吞作用,将配体与反义寡核苷酸(ASON)形成的转运复合物靶向运送到特定的细胞,使细胞内的ASON达到足够高的浓度,从而有效发挥反义抑制作用。本文简要综述对受体介导的反义治疗日前常用的受体、转运复合物的形成、内吞过程中需要解决的问题及实验研究进展。
- 受体 /
- 反义治疗 /
- 反义寡核苷酸
Abstract: Receptor can specifically bind its ligand with high affinyty.Based on this antisense oligonucleotides(ONs) linked to specific receptor ligand can be targeted to cells which possess specific receptor and enter into these cells by receptor-mediated endocytosis.Adequate intracellular concentrations of antisense ONs can be obtained enough to inhibit target gene expression. Receptors used frequently, formation of ONs delivery complexes, questions required to settle in the process of endocytosis and experiment studies of receptor mediated antisense therapy are concisely introduced in this article.
- receptor /
- antisense therapy /
- oligonuclides
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Wu GY, Wu CH. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system[J]. J Biol Chem, 1987, 262:4429~4432.
[2]	Madon J, Blum HE. Receptor-mediated delivery of hepatitis Bvirus DNA and antisense oligodeoxynucleotides to avian liver cells[J].Hepatology, 1996, 24:474~481.
[3]	Sugano M, Makino N. Changes in plasma lipoprotein cholesterol level by antisense oligodeoxynucleotides against cholesteryl ester transfer protein in cholesterol-fed rabbits[J]. J Biol Chem, 1996, 271:19080~19083.
[4]	Sugano M, Makino N, Sawada S, et al. Effect of antisense oligodeoxynucleotides against cholestryl ester tansfer protein on the development of atherosclerosis in cholesterol-fed rabbits[J]. J Biol Chem, 1998, 273:5033~5036.
[5]	Wagner E, Zenke M, Cotton M, et al. Teansferrin-polycation conjugates as carriers for DNA uptake into cells[J]. Proc Natl Acad Sci USA, 1990, 87:3410~3414.
[6]	Citro G, Perrotti D, Cucco C, et al. Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antiserse oligodeoxynucleotides[J].Proc Natl Acad Sci USA, 1992, 89:7031~7036.
[7]	Citro G, Ginobbi P, Candiloro A, et al. Chemical modification of ligands for cell receptors to introduce foreign compounds into the cells[J]. Dis Colon Rectum, 1994, 37(suppl):s127~s132.
[8]	Reddy JA, Low PS. Folate-mediated targeting of therapeutic andimaging agents to cancers[J]. Crit Rev Ther Carrier Syst, 1998, 15:587~627.
[9]	Ginobbi P, Geiser TA, Ombres D, et al. Folic acid-polylysine carrier improves efficacy of c-myc antisense[J]. Anticancer Res, 1997, 17(1A):29~35.
[10]	Wang S, Lee RJ, Cauchon G, et al. Delivery of antisense oligodeoxynucleotids against the human epidermal growth factor receptor into cultured KB cell with liposemes conjugated to folate via polyethylene glycol[J]. Proc Natl Acad Sci U SA, 1995, 92:3318~3312.
[11]	Cristiano RJ, Roth JA. Epidermal growth factor mediated DNA delivery into lung cells via the epidermal growth factor receptor[J]. Cancer Gene Ther, 1996, 3(1):4~10.
[12]	Liang WW, Shi X, Deshpande D, et al. Oligonucleotide targeting to alveolar macrophages by mannose receptor-mediated endocytosis[J]. Biophys Acta,1996, 1279(2):227~234.
[13]	Rojanasakul Y, Weissman DN, Shi X, et al. Antisense inhibition of silica-induced tumor necrosis factor in alveolar macrophages[J]. J Biol Chem, 1997, 272(2):3910~3914.
[14]	Miller N, Vile R. Targeted vectors for gene therapy[J]. Faseb J, 1995, 9:190~199.

[1]	郑建国 , 谭天秩 . 放射性核素反义治疗在恶性肿瘤中的应用. 国际放射医学核医学杂志, 1998, 22(6): 242-244.
[2]	夏劲松 . 反义显像技术的研究进展. 国际放射医学核医学杂志, 2001, 25(2): 62-65.
[3]	欧晓红 . 放射性核素反义治疗. 国际放射医学核医学杂志, 2002, 26(6): 246-248.
[4]	杨卫东 , 朱承谟 . 肿瘤反义显像技术中的若干问题. 国际放射医学核医学杂志, 1998, 22(6): 244-247.
[5]	柳江燕 , 陈雪红 . 肿瘤受体显像及介导靶向治疗的研究进展. 国际放射医学核医学杂志, 2005, 29(6): 258-260.
[6]	袁杰 , 刘兴党 , 韩梅 . SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用. 国际放射医学核医学杂志, 2013, 37(1): 30-33, 41. doi: 10.3760/cma.j.issn.1673-4114.2013.01.009
[7]	鲍伟奇 , 邱春 , 管一晖 . γ-氨基丁酸A型-苯二氮受体显像剂在神经系统疾病中的应用. 国际放射医学核医学杂志, 2012, 36(1): 1-8. doi: 10.3760/cma.j.issn.1673-4114.2012.01.001
[8]	侯敏 . 癫痫的PET受体显像. 国际放射医学核医学杂志, 2003, 27(4): 168-171.
[9]	王明芳 . 放射性示踪剂在脑功能PET显像中的应用. 国际放射医学核医学杂志, 2001, 25(6): 246-249.
[10]	孙义敏 , 卜桂兰 , 闵长庚 . ¹¹¹In标记反义寡核苷酸用于肿瘤显像的可能性研究:合成、稳定性、体内分布. 国际放射医学核医学杂志, 1997, 21(3): 120-121.

点击查看大图

计量

文章访问数: 1045
HTML全文浏览量: 88
PDF下载量: 2

受体介导的反义治疗研究

张春

作者简介:张春(1973-),女,山西长治人,华西医科大学附属第一医院核医学科住院医师,博士研究生,主要从事反义治疗研究。

610041 成都, 华西医科大学附一院核医学科

收稿日期: 2000-02-06

基金项目: 国家自然科学基金(39870200)

关键词:

摘要: 受体介导的反义治疗是利用受体与配体高特异性、高亲和力结合的特点,通过受体介导的内吞作用,将配体与反义寡核苷酸(ASON)形成的转运复合物靶向运送到特定的细胞,使细胞内的ASON达到足够高的浓度,从而有效发挥反义抑制作用。本文简要综述对受体介导的反义治疗日前常用的受体、转运复合物的形成、内吞过程中需要解决的问题及实验研究进展。